Proper name: Olanzapine Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): Schizophrenia and bipolar disorder Approval date: 1996 2006 Revenue: $4.364 billion Percentage of Eli Lilly’s Total Revenue: 27.81 percent Eli Lilly’s largest product, Zyprexa, is indicated for schizophrenia and acute mixed and manic episodes of bipolar I disorder, and for maintenance treatment of bipolar disorder. First approved in September 1996 for

Proper name: Amlodipine besylate Drug Developer: Pfizer Inc. Location: New York, New York Website: www.pfizer.com Indication(s): Hypertension Approval date: 1992 2006 Revenue: $4.866 billion Percentage of Pfizer’s Total Revenue: 10.06 percent Norvasc is the most prescribed branded medicine for hypertension in the world. It was approved on July 31, 1992, and its patent expired on January 31, 2007. In several European countries, the patent expired in 2003 and 2004. Sales of Norvasc

Proper name: Esomeprazole Drug Developer: AstraZeneca plc Location: London, UK Website: www.astrazeneca.com Indication(s): Gastroesophageal reflux disease (GERD), for the healing of erosive esophagitis, and for the treatment of heartburn and other GERD symptoms Approval date: 2001 2006 Revenue: $5.182 billion Percentage of AstraZeneca’s Total Revenue: 19.57 percent AstraZeneca plc’s healing purple pill, approved in February 2001, is indicated for the treatment of gastroesophageal reflux

Proper name: Salmeterol xinafoate/fluticasone propionate Drug Developer: GlaxoSmithKline plc Location: Brentford, UK Website: www.gsk.com Indication(s): Asthma and chronic obstructive pulmonary disease Approval date: 1998 2006 Revenue: $6.129 billion Percentage of GlaxoSmithKline’s Total Revenue: 13.2 percent GlaxoSmithKline plc’s Advair, branded as Seretide outside the U.S., is indicated for asthma and chronic obstructive pulmonary disease (COPD). It is a combination of Serevent and

Proper name: Clopidogrel Drug Developer: Sanofi-Aventis and Bristol-Myers Squibb Co. Location: Paris, France, and New York, New York Website: www.sanofi-aventis.com and www.bms.com Indication(s): Protection against heart attacks and strokes, peripheral arterial disease and acute coronary syndrome Approval date: 1997 2006 Revenue: Bristol-Myers Squibb: $3.257 billion Sanofi-Aventis: $3.016 billion Total: $6.272 billion Percentage of Bristol-Myers Squibb’s Total Revenue: 18.18 percent

Proper name: Atorvastatin Drug Developer: Pfizer Inc. Location: New York, New York Website: www.pfizer.com Indication(s): High cholesterol Approval date: 1996 2006 Revenue: $12.886 billion Percentage of Pfizer’s Total Revenue: 26.64 percent Pfizer Inc.’s Lipitor is the most widely used treatment for lowering cholesterol — an important indication in the U.S., where high cholesterol affects one in three people. First approved December 17, 1996, the drug is indicated for the reduction of

Proper name: Imiglucerase Type: Enzyme-replacement therapy Drug Developer: Genzyme Corp. Location: Cambridge, Mass. Website: www.genzyme.com Indication(s): Type 1 Gaucher’s disease Approval Date: May 1994 2006 Revenue: $1 billion Percentage of Genzyme’s Total Revenue: 31.38 percent Cerezyme and the orphan drug market Cerezyme, the enzyme-replacement therapy for Type I Gaucher’s disease, is Genzyme Corp.’s top-selling product. Although the worldwide patient population for the disease

Proper name: Cetuxima Type: Anticancer Drug Developer: ImClone Systems Inc. Location: New York, New York Website: www.imclone.com Indication(s): Colorectal cancer that has spread to other parts of the body in patients whose tumors express an epidermal growth factor receptor (EGFR); in combination with radiation therapy for head and neck cancer Approval Date: February 2004 2006 Revenue: $1.1 billion Percentage of ImClone Systems’ Total Revenue: 162.28 percent About Erbitux Erbitux was

Proper name: Palivizumab Type: Anti-infective Drug Developer: MedImmune Inc. Location: Gaithersburg, Maryland Website: www.medimmune.com Indication(s): For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease Approval Date: June 1998 2006 Revenue: $1.1 billion Percentage of MedImmune’s Total Revenue: 86.14 percent Respiratory syncytial virus Respiratory syncytial virus (RSV) is the most

Proper name: Peginterferon alfa-2a Type: Anti-viral Drug Developer: F. Hoffmann-La Roche Ltd. Location: Basel, Switzerland Website: www.roche.com Indication(s): For the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease, and for the treatment of adults with hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation. Approval Date: October 2002 2006 Revenue: $1.177 billion Percentage of Roche’s Total

Proper name: Emtricitabine and tenofovir disoproxil fumarate Type: Anti-HIV Developer: Gilead Sciences Inc. Location: Foster City, California Web address: www.gilead.com Indication(s): In combination with other antiretroviral agents for the treatment of HIV-1 infection Approval Date: August 2004 2006 Revenue: $1.19 billion Percentage of Gilead’s Total Revenue: 39.33 percent About HIV/AIDS In the U.S., more than 1.1 million people are infected with human immunodeficiency virus (HIV

Proper name: Filgrastim Type: Anticancer, anti-infective Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): For the treatment of chemotherapy-induced neutropenia, for bone marrow transplant accompanied by neutropenia, bone marrow transplant engraftment or failure, mobilization of autologous peripheral blood progenitor cells after chemotherapy and severe chronic neutropenia Approval Date: February 1991 2006 Revenue: $1.213 billion

Proper name: Insulin lispro Type: Insulin diabetes therapeutic Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For quick-response mealtime management of hyperglycemia in patients with diabetes mellitus Approval Date: June 1996 2006 Revenue: $1.3 billion Percentage of Eli Lilly’s Total Revenue: 8.29 percent Diabetes and Eli Lilly’s role In most people, the pancreas produces the hormone insulin, which is necessary for the body to

Proper name: Interferon beta-1b Type: Autoimmune drug Drug Developer: Chiron Corp. Location: Emeryville, California Website: www.chiron.com Indication(s): For the treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations Approval Date: August 1993 2006 Revenue: $1.311 billion Percentage of Bayer Schering’s Total Revenue: 17.24 percent Multiple sclerosis It’s a disease that afflicts those from colder climates more than more temperate

Proper name: Glatiramer acetate injection Type: Autoimmune drug Drug Developer: Teva Neuroscience Inc. Location: Kansas City, Missouri Website: www.tevaneuroscience.com Indication(s): For the reduction of relapses in relapsing-remitting multiple sclerosis Approval Date: December 1996 2006 Revenue: $1.414 billion Percentage of Teva’s Total Revenue: 16.82 percent About Copaxone Copaxone’s presence on the top biotech drug list is an example of biotech and pharma merging on a molecular

Proper name: Interferon beta-1a Type: Multiple sclerosis therapeutic Developer: Merck Serono SA Location: Geneva, Switzerland Web address: www.serono.com Indication(s): For interferon-specific disease modification in the treatment of relapsing multiple sclerosis to slow the development of physical disability and to decrease the frequency of exacerbations Approval Date: March 2002 2006 Revenue: $1.452 billion Percentage of Merck Serono’s Total Revenue: 51.76 percent About Rebif Rebif

Proper name: Interferon beta-1a Type: Autoimmune drug Drug Developer: Biogen Idec Inc. Location: Cambridge, Massachusetts Website: www.biogenidec.com Indication(s): Multiple sclerosis Approval Date: May 1996 2006 Revenue: $1.71 billion Percentage of Biogen Idec’s Total Revenue: 63.73 percent Multiple sclerosis statistics According to the National Multiple Sclerosis Society (NMSS), multiple sclerosis (MS) is considered as an autoimmune disorder, often contracted by genetic deposition

Proper name: Pneumococcal polysaccharide vaccine Type: Vaccine Drug Developer: Wyeth Location: Madison, New Jersey Website: www.wyeth.com Indication(s): Prevention of diseases caused by Streptococcus pneumoniae (pneumococcus) Approval Date: February 2000 2006 Revenue: $1.961 billion Percentage of Wyeth’s Total Revenue: 9.64 percent S. pneumoniae Diseases caused by Streptococcus pneumoniae (pneumococcus) include pneumonia, meningitis, ear infections and sinus infections. Annually

Proper name: Adalimumab Type: Anti-inflammatory agent Developer: Abbott Laboratories Location: Abbott Park, Illinois Web address: www.abbott.com Indication(s): For the treatment of rheumatoid arthritis or psoriatic arthritis Approval Date: December 2002 2006 Revenue: $2.044 billion Percentage of Abbott’s Total Revenue: 9.09 percent About Humira Humira has extended its indication by becoming the first and only self-administered biologic treatment for moderate-to-severe Crohn’s disease